Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas

Paul A. Christensen,[*,†,‡] Randall J. Olsen,[*,†,‡] S. Wesley Long,[*,†,‡] Sishir Subedi,[†] James J. Davis,[§,¶] Parsa Hodjat,[†] Debbie R. Walley,[†] Jacob C. Kinskey,[†] Matthew Ojeda Saavedra,[†] Layne Pruitt,[†] Kristina Reppond,[†] Madison N. Shyer,[†] Jessica Cambric,[†] Ryan Gadd,[†] Rashi M. Thakur,[†] Akanksha Batajoo,[†] Regan Mangham,[†] Sindy Pena,[†] Trina Trinh,[†] Prasanti Yerramilli,[†] Marcus Nguyen,[§,¶] Robert Olson,[§,¶] Richard Snehal,[†] Jimmy Gollihar,[†,#] James M. Musser.[†,‡,**]

**Contributed equally;*

[†]Laboratory of Human Molecular and Translational Human Infectious Diseases, Center for Infectious Diseases, Houston Methodist Research Institute and Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas 77030;

[‡]Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, 1300 York Avenue, New York City, New York 10065;

[§]Consortium for Advanced Science and Engineering, 22 University of Chicago, 5801 South Ellis Avenue, Chicago, Illinois, 60637;

[¶]*Computing, Environment and Life Sciences, Argonne National Laboratory, 9700 South Cass Avenue, Lemont, Illinois, 60439;*

[#]*DEVCOM Army Research Laboratory-South, Austin, Texas 78712*

[**]*Address correspondence to James M. Musser, M.D., Ph.D., Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, 6565 Fannin Street, Suite B490, Houston, Texas 77030. Tel: 713.441.5890, E-mail: jmmusser@houstonmethodist.org*

Running head: Delta variants and vaccine breakthrough

Disclosures: None.

Number of text pages: 15

Number of tables: 3

Number of figures: 4

Funding: This project was supported by the Houston Methodist Academic Institute Infectious Diseases Fund; and supported in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93019C00076 (J.J.D. and R.O.).

Abstract

Genetic variants of SARS-CoV-2 have repeatedly altered the course of the COVID-19 pandemic. Delta variants of concern are now the focus of intense international attention because they are causing widespread COVID-19 disease globally and are associated with vaccine breakthrough cases. We sequenced the genomes of 16,965 SARS-CoV-2 from samples acquired March 15, 2021 through September 20, 2021 in the Houston Methodist hospital system. This sample represents 91% of all Methodist system COVID-19 patients during the study period. Delta variants increased rapidly from late April onward to cause 99.9% of all COVID-19 cases and spread throughout the Houston metroplex. Compared to all other variants combined, Delta caused a significantly higher rate of vaccine breakthrough cases (23.7% for Delta compared to 6.6% for all other variants combined). Importantly, significantly fewer fully vaccinated individuals required hospitalization. Individuals with vaccine breakthrough cases caused by Delta had a low median PCR cycle threshold (Ct) value (a proxy for high virus load). This value was closely similar to the median Ct value for unvaccinated patients with COVID-19 caused by Delta variants, suggesting that fully vaccinated individuals can transmit SARS-CoV-2 to others. Patients infected with Alpha and Delta variants had several significant differences. Our integrated analysis emphasizes that vaccines used in the United States are highly effective in decreasing severe COVID-19 disease, hospitalizations, and deaths.

[Introduction]

Delta variants of concern (VOCs) of SARS-CoV-2 such as B.1.617.2, AY.3, and AY.4 are the focus of intense international concern because they are causing widespread COVID-19 disease in the United States, Southeast Asia, Europe, and elsewhere (https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html, last accessed: August 18, 2021; https://www.gov.uk/government/collections/new-sars-cov-2-variant, last accessed: August 18, 2021)[1]. For example, Delta has replaced the Alpha variant in the United Kingdom, previously the cause of virtually all COVID-19 cases in that country (https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021, last accessed August 18, 2021; https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveypilot/9july2021, last accessed August 18, 2021). Vaccine breakthrough cases caused by SARS-CoV-2 variants also have become of considerable public health and biomedical concern worldwide[2-6]. To study Delta spread and vaccine breakthrough cases in metropolitan Houston, we sequenced the genomes of 16,965 SARS-CoV-2 from patient samples acquired March 15, 2021 through September 20, 2021 using an Illumina NovaSeq 6000 instrument and methods described previously[7, 8]. This period includes the time from initial identification of Delta-related VOCs in late April in our large Houston Methodist healthcare system until Delta VOCs continuously caused the supermajority (99.9%) of all new cases. The sequenced sample is 91% of the 18,736 total COVID-19 cases diagnosed in our health system during the study period. We also compared characteristics of patients infected

with Alpha and Delta VOCs, an analysis that identified several significant differences between patients infected with these two variants.

Materials and Methods

Patient Specimens

Specimens were obtained from registered patients at Houston Methodist hospitals, associated facilities (e.g., urgent care centers), and institutions in the Houston metropolitan region that use our laboratory services. The great majority of individuals had signs or symptoms consistent with COVID-19 disease. For analyses focusing on the Delta family variants, a comprehensive sample of genomes obtained from March 15, 2021 through September 20, 2021 was used. This time frame was chosen because it represents the period during which the downturn of our third wave was occurring, and soon after we identified the first Delta variant case in our health care system. Subsequently, Delta variants increased rapidly to continuously cause 99.9% of all new cases. The study included 16,965 unique patients identified in this time frame for whom we had SARS-CoV-2 genome sequences. For analyses comparing features of patients infected with the Delta variants and Alpha VOC, a comprehensive sample of genomes obtained from January 1, 2021 through September 20, 2021 was used. This time frame represents the period during which we identified the first Alpha variant case in our

health care system. This VOC increased rapidly and peaked, and then decreased to cause less than 1% of all cases in the region. This part of the study included 28,560 unique patients identified in the January 1, 2021 through September 20, 2021 period. The work was approved by the Houston Methodist Research Institute Institutional Review Board (IRB1010-0199).

SARS-CoV-2 Molecular Diagnostic Testing

Specimens obtained from symptomatic patients with a suspicion for COVID-19 disease were tested in the Molecular Diagnostics Laboratory at Houston Methodist Hospital using assays granted Emergency Use Authorization (EUA) from the FDA (https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-diagnostic-testing-sars-cov-2#offeringtests, last accessed June 7, 2021). Multiple molecular testing platforms were used, including the COVID-19 test or RP2.1 test with BioFire Film Array instruments, the Xpert Xpress SARS-CoV-2 test using Cepheid GeneXpert Infinity or Cepheid GeneXpert Xpress IV instruments, the cobas SARS-CoV-2 & Influenza A/B Assay using the Roche Liat system, the SARS-CoV-2 Assay using the Hologic Panther instrument, the Aptima SARS-CoV-2 Assay using the Hologic Panther Fusion system, the Cobas SARS-CoV-2 test using the Roche 6800 system, and the SARS-CoV-2 assay using Abbott Alinity m instruments. Virtually all tests were performed on material obtained from nasopharyngeal swabs immersed in universal transport media (UTM); oropharyngeal or nasal swabs, bronchoalveolar lavage fluid, or sputum treated with dithiothreitol (DTT) were sometimes used. Standardized specimen

collection methods were used (https://vimeo.com/396996468/2228335d56, last accessed June 7, 2021).

SARS-CoV-2 Genome Sequencing

Libraries for whole SARS-CoV-2 genome sequencing were prepared according to version 3 or version 4 (https://community.artic.network/t/sars-cov-2-version-4-scheme-release/312, last accessed August 19, 2021) of the ARTIC nCoV-2019 sequencing protocol. Our semi-automated workflow described previously[7, 8] employed BioMek i7 liquid handling workstations (Beckman Coulter Life Sciences) and MANTIS automated liquid handlers (FORMULATRIX). Short sequence reads were generated with a NovaSeq 6000 instrument (Illumina). For continuity of the epidemiologic analysis in the study period, we included some genome sequences reported in a recent publication.[8]

SARS-CoV-2 Genome Sequence Analysis and Identification of Variants

Viral genomes were assembled with the BV-BRC SARS-Cov2 assembly service (https://www.bv-brc.org/app/ComprehensiveSARS2Analysis, last accessed June 7, 2021, requires registration). The One Codex SARS-CoV-2 variant calling and consensus assembly pipeline was used to assemble all sequences (https://github.com/onecodex/sars-cov-2.git, last accessed June 7, 2021) using default parameters and a minimum read depth of 3. Briefly, the pipeline uses seqtk version 1.3-r116 for sequence trimming (https://github.com/lh3/seqtk.git, last accessed June 7,

2021); minimap version 2.1 for aligning reads against reference genome Wuhan-Hu-1 (NC_045512.2); samtools version 1.11 for sequence and file manipulation; and iVar version 1.2.2 for primer trimming and variant calling. Genetic lineages, VOCs, and variants of interest (VOIs) were identified based on genome sequence data and designated by Pangolin v. 3.1.11 with pangoLEARN module 2021-08-09 (https://cov-lineages.org/resources/pangolin.html, last accessed August 18, 2021).

There is a known problem with the ARTIC V3 primer set that results in lack of detection or ambiguity of the G142D and D950N single nucleotide variants, even though these amino acid changes (142D and 950N) are present in the overwhelming majority of B.1.617.2 Delta variant isolates (https://community.artic.network/t/sars-cov-2-version-4-scheme-release/312, last accessed September 1, 2021, https://outbreak.info/compare-lineages?pango=B.1.617.2&gene=S&threshold=0.2, last accessed September 1, 2021). After we transitioned to ARTIC V4, we observed that all Delta variant strain haplotypes contained both 142D and 950N polymorphisms except for four isolates, two of which lacked 142D and two which lacked 950N. We recently reported an analysis that confirmed the previously identified ARTIC V3 problem[9]. Thus, for the Delta isolates presented here, virtually all samples sequenced with ARTIC V3 are presumed to have G142D and D950N.

Patient Metadata and Geospatial Analysis

Patient metadata (**Table 1, Table 2, Table 3**) were acquired from the electronic medical record by standard informatics methods. Patient home address zip codes were used to

visualize the geospatial distribution of spread for each VOC and VOI. Figures were generated with Tableau version 2020.3.4 (Tableau Software, LLC, Seattle, WA). A vaccination breakthrough case was defined as a PCR-positive sample from a patient obtained greater than 14 days after full vaccination (i.e., both doses of the Pfizer or Moderna mRNA vaccines) was completed. For some cases, manual chart review was conducted to resolve discrepancies or ambiguities.

Results

Delta Epidemiologic Wave

The first Houston Methodist patient infected with a Delta family variant was identified in mid-April 2021, a time when the Alpha VOC was responsible for most COVID-19 cases in metropolitan Houston, and the area was experiencing a steady downturn in total number of new COVID-19 cases (**Figure 1**). Delta VOCs slowly increased in frequency, but beginning in early July a sharp uptick of COVID-19 cases caused by these VOCs occurred (**Figure 1, Figure 2**), with an estimated doubling time of approximately seven days. By September 20, the genome data showed that Delta VOCs accounted for 99.9% of all new COVID-19 cases in our health system (**Figure 2**). This represents the fourth wave of COVID-19 cases in metropolitan Houston (**Figure 1**).

During the study period 18,736 COVID-19 cases were diagnosed in our healthcare system, and we sequenced 16,965 SARS-CoV-2 genomes, representing

91% of cases. We identified 13,043 patients (76.9% of the total sequenced) with Delta VOCs (Table 1A). The majority (62%; 2,418 of 3,922) of the non-Delta COVID-19 cases occurring during the study period were caused by the Alpha (UK B.1.1.7) VOC.

Consistent with extensive infections caused by Delta variants in Southeast Asia and elsewhere (https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html, last accessed: August 18, 2021; https://www.gov.uk/government/collections/new-sars-cov-2-variant, last accessed: August 18, 2021)[1], several patients had very recent travel histories to countries with a high prevalence of these VOCs, suggesting acquisition abroad and importation into Houston. Sixty patients with Delta Plus (Delta plus the K417N spike amino acid substitution) were identified.

To understand the geospatial distribution of Delta in metropolitan Houston, we acquired patient metadata from the electronic medical record by standard informatics methods, and home address zip codes were used to visualize virus spread (**Figure 2**). Delta VOCs were widely distributed throughout metropolitan Houston, with 334 distinct zip codes represented (**Figure 2**), indicative of the ability of Delta variants to spread very effectively and rapidly between individuals. Analysis of Delta VOCs dissemination over time illustrated the rapid spread of these variants throughout the Houston metroplex (**Figure 2**).

Delta Family Subvariants

A total of 1,236 subvariants was identified based on amino acid changes in spike protein. The seven most common identified in our study are shown (**Figure 3**) and these represented 73% of the 13,043 Delta samples. It is possible that the unexpectedly high number of subvariants reflects several contributing factors, including the large population sizes and genetic diversity of Delta globally, and multiple independent introductions into the Houston area. Other factors that in principle may contribute to subvariant generation and survival include high virus load in patients on initial diagnosis (**Table 1**), infection of partially immunized hosts, and prolonged infections occurring in relatively immunocompromised individuals[10-16]. In this regard, some of our patients had a history of cancer and organ transplants (**data not shown**). Patients infected with the same subvariant usually lived in different zip codes and generally had no apparent epidemiological link, consistent with the ability of Delta to spread very rapidly. In some cases there were clear epidemiologic links between patients infected with the same subvariant, including being members of the same household.

There is a considerable lack of detailed information about patients in the United States with COVID-19 caused by Delta VOCs (https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021, last accessed August 18, 2021). Compared to all other patients in the time frame studied, there was no significant difference in sex, but patients infected with Delta were significantly but modestly younger (**Table 1**). However, Delta variant patients were admitted significantly less frequently than other patients and had a significantly longer median hospital length of stay, but there was no significant difference in mortality rate (**Table 1**). Delta cases were more likely to be Asian (consistent with multiple recent

entry points from abroad) and Caucasian and less likely to be Hispanic or Latino, have significantly lower PCR cycle threshold (Ct) values on initial diagnosis (a proxy for higher virus load, a finding consistent with increased transmissibility of Delta variants). In addition, Delta variants caused a significantly much higher rate of vaccine breakthrough cases (23.7% compared to 6.6% for all other variants combined) (**Table 1**). Consistent with Delta causing an increased number of vaccine breakthrough cases, it has been reported that this variant has reduced sensitivity to antibody neutralization *in vitro*[14].

Comparison of Delta and Alpha COVID-19 Cases

The occurrence of a prominent third wave of COVID-19 cases in Houston caused by the Alpha VOC (**Figure 1**) provided the opportunity of compare and contrast large disease waves caused by two genetically distinct SARS-CoV-2 genotypes. For this analysis we included Alpha VOC cases beginning January 1, 2021, because that time was soon after our first recorded Houston Methodist case caused by this variant. The number of Delta cases studied (n = 13,043) was much greater than the number of Alpha cases (n = 3,238) (**Table 2**). The two patient populations differed significantly in many characteristics, including median age, ethnicity, median PCR Ct level, admission rates, maximum respiratory support, rate of vaccine breakthrough, median length of stay, and mortality (**Table 2**).

Vaccine Breakthrough Cases

We next analyzed vaccine breakthrough cases (**Table 3**). We found 3,346 of the 16,965 total patients (19.7%) for whom we have genome sequence data met the CDC definition of vaccine breakthrough cases (**Table 1 and Table 3**). There was no simple relationship between the time elapsed since administration of the second booster vaccination and the date of vaccination breakthrough (data not shown). These 3,346 patients received either the Pfizer-BioNTech BNT162b2 (*n* = 2,829, 85%), Moderna mRNA-1273 (*n* = 365, 11%), or J&J/Janssen JNJ-78436735 (*n* = 147, 4%) vaccine; vaccine type was not specified for five individuals. This distribution generally reflects the great majority of BNT162b2 vaccination doses given in our health system and should not be interpreted to mean that the Pfizer-BioNTech and Moderna products are unusually prone to breakthrough cases, as these mRNA vaccines are highly efficacious[6, 17-23]. Vaccinated patients infected with non-Delta variants had a significantly higher Ct value on initial diagnosis, likely indicating better vaccine protection, lower virus load, and decreased probability of transmission. Compared to all other variants combined, a significantly lower percentage (25.9% compared to 37.2%; *P*=0.0001) of patients with breakthrough cases caused by Delta variants was admitted to the hospital (**Table 1 and Table 3**).

Lambda and Mu Variants of Interest

The Lambda variant of interest was first reported in November 2020. It has very recently attracted widespread media and public interest because it has caused large numbers of infections in Peru and Ecuador, and has been reported to cause COVID-19 in the U.S[24,

[25] (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/, last accessed September 2, 2021). There has been speculation that Lambda may become numerically prominent in the United States and other countries, in part because its spike protein differs immunologically and has been reported to be partially resistant *in vitro* to vaccine-induced sera and therapeutic monoclonal antibodies[26-28]. Because of this concern, we inspected our large genome sequence database to determine if Lambda was present, and if so, had it increased substantially in the Houston metropolitan region. The analysis identified only eight cases caused by this variant of interest, the first one identified in our Houston Methodist patient population in mid-July 2021 (**Figure 4A**). These patients lived in several non-contiguous zip codes throughout the metroplex, that is, were not restricted to a single geographic area of greater Houston (**Figure 4A, B**). The Mu VOI was initially identified in Colombia in January, 2021, and has been reported to account for 39% of cases in that country[29]. Mu also has been found in many other countries worldwide, and recently it was reported that the Mu variant has increased resistance *in vitro* to antibodies elicited by vaccination with BNT162b2 and natural infection by SARS-CoV-2[30]. We identified 53 cases of COVID-19 caused by the Mu VOI, and similar to the Lambda these cases were distributed in multiple areas in the Houston metropolitan region (**Figure 4C, D**).

Discussion

In this work, we analyzed SARS-CoV-2 Delta VOCs population genomics and patient characteristics for 16,965 patients, focusing on mid-March 2021 through late September 2021, a time frame in which there was total replacement of the previously dominant Alpha (B.1.1.7) VOC by Delta family VOCs. During this six-month period, a substantial increase in COVID-19 cases occurred in our healthcare system and throughout all of the Houston metropolitan area, virtually all driven by rapid dissemination of the highly contagious Delta family variants. The study was based predominantly on genome sequence analysis of 16,965 SARS-CoV-2 samples from socioeconomically, geographically, and ethnically diverse patients. Several key findings were made, including (i) Delta family VOCs supplanted the Alpha VOC in a relatively short period of time, (ii) regardless of vaccination status, on initial diagnosis, compared to patients infected by other VOCs, patients infected by Delta VOCs had significantly lower Ct values, likely indicating significantly higher viral load in the nasopharynx, (iii) Delta caused significantly more vaccine breakthrough cases than other VOCs, (iv) significantly fewer fully vaccinated individuals required hospitalization, (v) the Lambda and Mu VOIs were identified but were very rare, and they did not increase to substantial levels in the time frame studied.

Our genome sequence data document a rapid increase of Delta variant cases in metropolitan Houston and a corresponding decrease of COVID-19 cases caused by Alpha and other variants, findings similar to epidemiologic trends observed in the UK (https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021, last accessed August 18, 2021; https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions

anddiseases/bulletins/coronaviruscovid19infectionsurveypilot/9july2021, last accessed August 18, 2021). In less than five months, Delta VOCs increased from an initial documented case in our large patient population to cause 99.9% of all cases in our healthcare system. The rapid increase in Delta cases we documented is responsible for a prominent fourth wave of COVID-19 disease in Houston that is ongoing (**Figure 1**). Our findings are consistent with Delta VOCs epidemiologic data reported from other regions of the US.

We found that Delta was significantly more likely to cause vaccine breakthrough cases (**Table 1 and Table 3**). However, importantly, 19.7% of all of our 16,965 COVID-19 cases with genome sequence data occurred in fully vaccinated individuals, but importantly only a small number (n = 896; 5.3%) of these patients required hospitalization. Vaccine breakthrough cases have emerged as an area of great interest, especially so with the increasing percentage of COVID-19 cases caused by Delta variants and the recognition that they are important causes of breakthroughs[31-36]. Although our analysis did not identify a simple relationship between the time elapsed since administration of the second booster vaccination and the date of vaccination breakthrough, this is an important area for continued study. Similarly, we did not study the potential relationship between vaccination breakthrough and waning immunity, but studies of this topic are ongoing.

Some investigators have speculated that the Lambda and Mu variants may become a major concern in future surges. Although in principle this is possible, our data show that neither variant has increased substantially in our metropolitan area during the

time frame studied. Thus, our genome analysis of a large set of samples from the first nine months of 2021 does not currently support this speculation, although circumstances may change in the future. Because we are sequencing the genome of the great majority of SARS-CoV-2 causing COVID-19 in our diverse patient population, we are continuously monitoring the growth trajectory of these and other variants in a major metropolitan region in the US. Thus, our ongoing near-real-time sequencing of SARS-CoV-2 genomes responsible for COVID-19 cases in metropolitan Houston provides a facile strategy to assess changes in the virus population composition and molecular evolution in this populous area.

Our study has several limitations that should be noted. Although we sequenced the genomes of SARS-CoV-2 causing 91% of all Houston Methodist COVID-19 cases in the study period, this sample represents only approximately 5% of cases reported in the metropolitan region. We believe it is possible that our patient populations underrepresent certain demographic groups, for example including homeless individuals and pediatric patients. The great majority of the samples sequenced in this study were obtained from symptomatic patients. Thus, it is possible that our sample failed to identify virus genotypes that are preferentially represented in asymptomatic individuals. However, given that at the end of the study Delta represented 99.9% of all cases, we think it unlikely that variants associated with asymptomatic individuals would be substantially different, although this is a formal possibility.

In the aggregate, our data add critical new information to the finding that these three vaccines are highly efficacious in decreasing severe COVID-19 disease,

hospitalizations, and deaths[6, 20, 23]. Further, the present study highlights the importance of analyzing SARS-CoV-2 genome data integrated with linked patient metadata and stresses the need to continue to do this in near-real time as the pandemic continues, the virus evolves, and new variants with potentially increased fitness are generated. Analyses of this type are also important in the context of vaccine formulation and long COVID, an increasing health and economic problem globally.

Acknowledgments

We thank Drs. Marc Boom and Dirk Sostman for their ongoing support and Dr. Sasha Pejerrey for editorial contributions and Dr. Heather McConnell for help with figures. The research was supported by the Houston Methodist Academic Institute Infectious Diseases Fund and many generous Houston philanthropists. James J. Davis was funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93019C00076. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

The findings and conclusions in this article are those of the authors and do not necessarily reflect the views of the U.S. Army.

We declare that we have no conflict of interest.

Author Contributions

P.A.C., R.J.O., S.W.L., S.S., and J.M.M. had full access to all study data and take responsibility for the integrity of the data and the accuracy of the data analysis; concept and design by J.M.M., P.A.C., R.J.O., and S.W.L; data acquisition, analysis, or interpretation by all authors; drafting of the manuscript by all authors; statistical analysis by P.A.C.; funding obtained by J.M.M. and J.J.D.; overall supervision by J.M.M; P.A.C., R.J.O., and S.W.L. contributed equally and are co-first authors.

Institutional Review Board statement: This work was approved by the Houston Methodist Research institutional review board (IRB1010-0199).

Additional Information: Genome data used in this study have been deposited to GISAID.

References

[1] Dhar MS, Marwal R, Radhakrishnan V, Ponnusamy K, Jolly B, Bhoyar RC, Fatihi S, Datta M, Singh P, Sharma U, Ujjainia R, Naushin S, Bhateja N, Divakar MK, Sardana V, Singh MK, Imran M, Senthivel V, Maurya R, Jha N, Mehta P, Rophina M, Arvinden V, Chaudhary U, Thukral L, Pandey R, Dash D, Faruq M, Lall H, Gogia H, Madan P, Kulkarni S, Chauhan H, Sengupta S, Kabra S, Consortium TIS-C-G, Singh SK, Agrawal A, Rakshit P: Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. medRxiv 2021:2021.06.02.21258076.

[2] Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, Schaefer-Babajew DJ, DaSilva J, Muecksch F, Gaebler C, Lifton R, Nussenzweig MC, Hatziioannou T, Bieniasz PD, Darnell RB: Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med 2021, 384:2212-8.

[3] Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, Elbaz M, Nesher L, Stein M, Maor Y, Cohen R, Hussein K, Weinberger M, Zimhony O, Chazan B, Najjar R, Zayyad H, Rahav G, Wiener-Well Y: BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect 2021.

[4] COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021. MMWR Morb Mortal Wkly Rep 2021, 70:792-3.

[5] Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, Caspi I, Levy R, Leshchinsky M, Ken Dror S, Bergerzon G, Gadban H, Gadban F, Eliassian E, Shimron O, Saleh L, Ben-Zvi H, Keren Taraday E, Amichay D, Ben-Dor A, Sagas D, Strauss M, Shemer Avni Y, Huppert A, Kepten E, Balicer RD, Netzer D, Ben-Shachar S, Stern A:

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med 2021, Aug;27(8):1379-1384.

[6] Tenforde MW, Patel MM, Ginde AA, Douin DJ, Talbot HK, Casey JD, Mohr NM, Zepeski A, Gaglani M, McNeal T, Ghamande S, Shapiro NI, Gibbs KW, Files DC, Hager DN, Shehu A, Prekker ME, Erickson HL, Exline MC, Gong MN, Mohamed A, Henning DJ, Peltan ID, Brown SM, Martin ET, Monto AS, Khan A, Hough CT, Busse L, Ten Lohuis CC, Duggal A, Wilson JG, Gordon AJ, Qadir N, Chang SY, Mallow C, Gershengorn HB, Babcock HM, Kwon JH, Halasa N, Chappell JD, Lauring AS, Grijalva CG, Rice TW, Jones ID, Stubblefield WB, Baughman A, Womack KN, Lindsell CJ, Hart KW, Zhu Y, Olson SM, Stephenson M, Schrag SJ, Kobayashi M, Verani JR, Self WH: Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States. Clin Infect Dis 2021.

[7] Long SW, Olsen RJ, Christensen PA, Subedi S, Olson R, Davis JJ, Saavedra MO, Yerramilli P, Pruitt L, Reppond K, Shyer MN, Cambric J, Finkelstein IJ, Gollihar J, Musser JM: Sequence Analysis of 20,453 Severe Acute Respiratory Syndrome Coronavirus 2 Genomes from the Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple Isolates of All Major Variants of Concern. Am J Pathol 2021, 191:983-92.

[8] Olsen RJ, Christensen PA, Long SW, Subedi S, Hodjat P, Olson R, Nguyen M, Davis JJ, Yerramilli P, Saavedra MO, Pruitt L, Reppond K, Shyer MN, Cambric J, Gadd R, Thakur RM, Batajoo A, Finkelstein IJ, Gollihar J, Musser JM: Trajectory of Growth of Severe Acute Respiratory (SARS-CoV-2) Syndrome Coronavirus 2 Variants in Houston,

Texas, January through May 2021, Based on 12,476 Genome Sequences. Am J Pathol 2021, 191(10):1754-1773.

[9] Davis JJ, Long SW, Christensen PA, Olsen RJ, Olson R, Shukla M, Subedi S, Stevens R, Musser JM: Analysis of the ARTIC version 3 and version 4 SARS-CoV-2 primers and their impact on the detection of the G142D amino acid substitution in the spike protein. bioRxiv 2021:2021.09.27.461949.

[10] Clark SA, Clark LE, Pan J, Coscia A, McKay LGA, Shankar S, Johnson RI, Brusic V, Choudhary MC, Regan J, Li JZ, Griffiths A, Abraham J: SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. Cell 2021, 184:2605-17.e18.

[11] Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, Solomon IH, Kuo HH, Boucau J, Bowman K, Adhikari UD, Winkler ML, Mueller AA, Hsu TY, Desjardins M, Baden LR, Chan BT, Walker BD, Lichterfeld M, Brigl M, Kwon DS, Kanjilal S, Richardson ET, Jonsson AH, Alter G, Barczak AK, Hanage WP, Yu XG, Gaiha GD, Seaman MS, Cernadas M, Li JZ: Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med 2020, 383:2291-3.

[12] Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman MA, Wobus CE, Adams M, Washer L, Martin ET, Lauring AS: Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient. J Infect Dis 2021, 223:23-7.

[13] Hensley MK, Bain WG, Jacobs J, Nambulli S, Parikh U, Cillo A, Staines B, Heaps A, Sobolewski MD, Rennick LJ, Macatangay BJC, Klamar-Blain C, Kitsios GD, Methé B, Somasundaram A, Bruno TC, Cardello C, Shan F, Workman C, Ray P, Ray A, Lee J,

Sethi R, Schwarzmann WE, Ladinsky MS, Bjorkman PJ, Vignali DA, Duprex WP, Agha ME, Mellors JW, McCormick KD, Morris A, Haidar G: Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study. Clinical Infectious Diseases 2021, 73(3):e815-e821.

[14] Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, Porrot F, Robillard N, Puech J, Prot M, Gallais F, Gantner P, Velay A, Le Guen J, Kassis-Chikhani N, Edriss D, Belec L, Seve A, Courtellemont L, Péré H, Hocqueloux L, Fafi-Kremer S, Prazuck T, Mouquet H, Bruel T, Simon-Lorière E, Rey FA, Schwartz O: Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 2021, 596(7871):276-280.

[15] Kemp SA, Collier DA, Datir RP, Ferreira IATM, Gayed S, Jahun A: SARS-CoV-2 evolution during treatment of chronic infection. Nature 2021, 592:277-82.

[16] Ghedin E, Nussenblatt V, Roder A, Das S, de Wit E, Youn J-H, Banakis S, Muchegian A, Mederos C, Wang W, Chung M, Perez-Perez L, Palmore T, Brudno J, Kochenderfer J: Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B cell depletion. medRxiv 2021:2021.10.02.21264267.

[17] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine 2020, 383:2603-15.

[18] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2020, 384:403-16.

[19] Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021, 397:99-111.

[20] Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, Myers R, Campbell CNJ, Amirthalingam G, Edmunds M, Zambon M, Brown KE, Hopkins S, Chand M, Ramsay M: Effectiveness of

Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med 2021, 385:585-594.

[21] Abu-Raddad LJ, Chemaitelly H, Butt AA: Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med 2021, 385:187-9.

[22] Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD: BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med 2021, 384:1412-23.

[23] Jagadeesh Kumar V, Sowpati DT, Munigela A, Banu S, Siva AB, Sasikala M, Nutalapati C, Kulkarni A, Mukherjee P, Zaveri L, Team CC-, Team AHC-Vs, Tallapaka KB, Reddy DN: Clinical outcomes in vaccinated individuals hospitalized with Delta variant of SARS-CoV-2. medRxiv 2021:2021.07.13.21260417.

[24] Padilla-Rojas C, Jimenez-Vasquez V, Hurtado V, Mestanza O, Molina IS, Barcena L, Morales Ruiz S, Acedo S, Lizarraga W, Bailon H, Cáceres O, Galarza M, Rojas-Serrano N, Vargas-Herrera N, Lope-Pari P, Huayra J, Solari L: Genomic analysis reveals a rapid spread and predominance of lambda (C.37) SARS-COV-2 lineage in Peru despite circulation of variants of concern. J Med Virol 2021, 1-5.

[25] Romero PE, Dávila-Barclay A, Salvatierra G, González L, Cuicapuza D, Solis L, Marcos-Carbajal P, Huancachoque J, Maturrano L, Tsukayama P: The Emergence of SARS-CoV-2 Variant Lambda (C.37) in South America. medRxiv 2021:2021.06.26.21259487.

[26] Tada T, Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR: The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial

Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies. bioRxiv 2021:2021.05.14.444076.

[27] Kimura I, Kosugi Y, Wu J, Yamasoba D, Butlertanaka EP, Tanaka YL, Liu Y, Shirakawa K, Kazuma Y, Nomura R, Horisawa Y, Tokunaga K, Takaori-Kondo A, Arase H, Consortium TGtPJ, Saito A, Nakagawa S, Sato K: SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance. bioRxiv 2021:2021.07.28.454085.

[28] Liu H, Wei P, Zhang Q, Aviszus K, Linderberger J, Yang J, Liu J, Chen Z, Waheed H, Reynoso L, Downey GP, Frankel SK, Kappler J, Marrack P, Zhang G: The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines. bioRxiv 2021:2021.08.25.457692.

[29] Laiton-Donato K, Franco-Muñoz C, Álvarez-Díaz DA, Ruiz-Moreno HA, Usme-Ciro JA, Prada DA, Reales-González J, Corchuelo S, Herrera-Sepúlveda MT, Naizaque J, Santamaría G, Rivera J, Rojas P, Ortiz JH, Cardona A, Malo D, Prieto-Alvarado F, Gómez FR, Wiesner M, Martínez MLO, Mercado-Reyes M. Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2. Infect Genet Evol. 2021, 95:105038.

[30] Uriu K, Kimura I, Shirakawa K, Takaori-Kondo A, Nakada T-a, Kaneda A, Consortium TGtPJ, Nakagawa S, Sato K: Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera. bioRxiv 2021:2021.09.06.459005.

[31] Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, Sabo RT, Hall N, Foreman A, Schubert PL, Gallagher GR, Fink T, Madoff LC, Gabriel SB, MacInnis B, Park DJ, Siddle KJ, Harik V, Arvidson D, Brock-Fisher T, Dunn M, Kearns A, Laney AS: Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough

Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep 2021, 70:1059-62.

[32] Chia PY, Xiang Ong SW, Chiew CJ, Ang LW, Chavatte J-M, Mak T-M, Cui L, Kalimuddin S, Chia WN, Tan CW, Ann Chai LY, Tan SY, Zheng S, Pin Lin RT, Wang L, Leo Y-S, Lee VJ, Lye DC, Young BE: Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study. medRxiv 2021:2021.07.28.21261295.

[33] Sheikh A, McMenamin J, Taylor B, Robertson C: SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 2021, 397:2461-2.

[34] Riemersma KK, Grogan BE, Kita-Yarbro A, Halfmann PJ, Segaloff HE, Kocharian A, Florek KR, Westergaard R, Bateman A, Jeppson GE, Kawaoka Y, O'Connor DH, Friedrich TC, Grande KM: Shedding of Infectious SARS-CoV-2 Despite Vaccination. medRxiv 2021:2021.07.31.21261387.

[35] Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, Mandelboim M, Gal Levin E, Rubin C, Indenbaum V, Tal I, Zavitan M, Zuckerman N, Bar-Chaim A, Kreiss Y, Regev-Yochay G: Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N Engl J Med 2021.

[36] Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, Milo R, Alroy-Preis S, Ash N, Huppert A: Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel. medRxiv 2021:2021.08.24.21262423.

Figure Legends

Figure 1 Epidemiologic curve showing four COVID-19 disease waves in Houston Methodist patients. Number of new COVID-19 cases (y-axis) totals are shown as a +/- three-day moving average. Each of the four waves is shown in a different color simply as a stylistic device. The first and second waves were composed of a heterogenous array of SARS-CoV-2 genotypes. The Alpha variant shown in the third wave and the Delta variant shown in the fourth indicate their numeric prominence in those waves, and should not be interpreted to mean that all cases in the third and fourth waves were caused by Alpha and Delta VOCs, respectively. The fourth wave shown includes data through September 20, 2021. The figure was generated with Tableau version 2020.3.4 (Tableau Software, LLC, Seattle, WA). The curve mirrors that of disease activity in metropolitan Houston, Texas.

Figure 2 Increase in Delta frequency over time and distribution in metropolitan Houston. The study time frame was March 15, 2021 through September 20, 2021. **A:** Cumulative increase in Delta during the study period; y-axis is the cumulative number of new COVID-19 cases. At the end of the study period, Delta continuously caused 99.9% of all COVID-19 cases. **B – E:** Geospatial distribution of Delta based on home address zip code for each patient. **B**: April 15 – May 15; **C**: April 15 – June 15; **D**: April 15 – July 15; **E**: April 15 – August 15; **F**: April 15 – September 20. Note differences in heat map scale for each panel. Figures were generated using Tableau version 2020.3.4. (Tableau Software, LLC, Seattle, WA).

Figure 3 Structural changes present in spike protein of the seven most abundant Delta subvariants identified in the study. The numbers denote the number of patients with each subvariant identified in this study. These seven subvariants represented 73% of the 13,043 Delta samples identified in the study. In this figure, we included all subvariants represented by at least 100 samples. S1-NTD, S1 domain-aminoterminal domain; S1-RBD, S1 domain-receptor binding domain; S1, S1 domain; S2, S2 domain. The figure is a modified version of one published previously[8].

Figure 4 Lambda and Mu variants identified in metropolitan Houston in our patient population. **A:** cumulative increase in the cases caused by Lambda variants identified in the study; **B:** geospatial distribution of these Lambda variants based on the home address zip code for each patient. **C:** cumulative increase in cases caused by the Mu variants identified in the study; **D:** geospatial distribution of the Mu variants based on the home address zip code for each patient. Figures were generated using Tableau version 2020.3.4. (Tableau Software, LLC, Seattle, WA).

Table 1. Summary of pertinent patient metadata for the 16,965 unique patients

	Delta Variant	Other Variants	Total	Statistical Analysis
No. (%) with data	13043 (76.9%)	3922 (23.1%)	16965	
Patient Characteristics				
Median Age (Years)	46.7	47.9	47.0	*P*=0.0114 Mann-Whitney
Female	6986 (53.6%)	2033 (51.8%)	9019 (53.2%)	*P*=0.0578 Fisher's exact test
Male	6057 (46.4%)	1889 (48.2%)	7946 (46.8%)	
Ethnicity				
Caucasian	5657 (43.5%)	1533 (39.4%)	7190 (42.6%)	*P*<0.0001 Chi-square
Hispanic or Latino	3395 (26.1%)	1199 (30.8%)	4594 (27.2%)	
Black	2908 (22.4%)	913 (23.4%)	3821 (22.6%)	
Asian	493 (3.8%)	113 (2.9%)	606 (3.6%)	
Native American	24 (0.2%)	15 (0.4%)	39 (0.2%)	
Hawaiian/Pacific Islander	32 (0.2%)	6 (0.2%)	38 (0.2%)	
Unavailable	492 (3.8%)	116 (3.0%)	608 (3.6%)	
BMI				
Median BMI	29.6	30.3	29.8	*P*<0.0001 Mann-Whitney
Admission Data				
Admitted	5184 (39.7%)	2118 (54.0%)	7302 (43.0%)	*P*<0.0001 Fisher's exact test Odds Ratio: 0.554 (95% CI 0.511-0.600)
Not Admitted	7859 (60.3%)	1804 (46.0%)	9663 (57.0%)	
Median LOS (Days)	5.7	5.0	5.3	*P*<0.0001 Mann-Whitney
Max Respiratory Support				
ECMO	16 (0.3%)	7 (0.3%)	23 (0.3%)	*P*<0.0001 Chi-square
Mechanical Ventilation	555 (10.7%)	167 (7.9%)	722 (9.9%)	

Non-Invasive Ventilation	501 (9.7%)	187 (8.8%)	688 (9.4%)	
High Flow Oxygen	1450 (28.0%)	402 (19.0%)	1852 (25.4%)	
Low Flow Oxygen	1741 (33.6%)	876 (41.4%)	2617 (35.8%)	
Room Air	921 (17.8%)	479 (22.6%)	1400 (19.2%)	
Mortality				
Alive	12496 (95.8%)	3755 (95.7%)	16251 (95.8%)	*P*=0.8561 Fisher's exact test Odds Ratio: 0.896 (95% CI 0.739-1.087)
Deceased	547 (4.2%)	167 (4.3%)	714 (4.2%)	
Median PCR Cycle Threshold				
Abbott Alinity	21.0 n=4200	25.6 n=1408	n=5608	*P*<0.0001 Mann-Whitney
Hologic Panther	21.9 n=1140	26.0 n=473	n=1613	*P*<0.0001 Mann-Whitney
Vaccine				
No vaccine	9483 (72.7%)	3509 (89.5%)	12992 (76.6%)	*P*<0.0001 Chi-square
>7 days past 1st vaccine	472 (3.6%)	155 (4.0%)	627 (3.7%)	
>14 days past 2nd vaccine	3088 (23.7%)	258 (6.6%)	3346 (19.7%)	

Data include 16,965 unique patients with high-quality sequence results between March 15, 2021 and September 20, 2021. BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay

Table 2. Comparison of pertinent patient metadata for 16,281 unique Delta VOC and Alpha VOC patients

	Delta Variant	Alpha Variant	Total	Statistical Analysis
No. (%) with data	13043 (80.1%)	3238 (19.9%)	16281	
Patient Characteristics				
Median Age (Years)	46.7	49.4	47.3	*P*<0.0001 Mann-Whitney
Female	6986 (53.6%)	1698 (52.4%)	8684 (53.3%)	*P*=0.2538 Fisher's exact test
Male	6057 (46.4%)	1540 (47.6%)	7597 (46.7%)	
Ethnicity				
Caucasian	5657 (43.5%)	1269 (39.4%)	6926 (42.7%)	*P*<0.0001 Chi-square
Hispanic or Latino	3395 (26.1%)	961 (29.8%)	4356 (26.9%)	
Black	2908 (22.4%)	757 (23.5%)	3665 (22.6%)	
Asian	493 (3.8%)	126 (3.9%)	619 (3.8%)	
Native American	24 (0.2%)	12 (0.4%)	36 (0.2%)	
Hawaiian/Pacific Islander	32 (0.2%)	4 (0.1%)	36 (0.2%)	
Unavailable	492 (3.8%)	91 (2.8%)	583 (3.6%)	
BMI				
Median BMI	29.6	30.5	29.8	*P*<0.0001 Mann-Whitney
Admission Data				
Admitted	5184 (39.7%)	1721 (53.2%)	6905 (42.4%)	*P*<0.0001 Fisher's exact test Odds Ratio: 0.581 (95% CI 0.538-0.628)
Not Admitted	7859 (60.3%)	1517 (46.8%)	9376 (57.6%)	
Median LOS (Days)	5.7	5.1	5.4	*P*=0.0031 Mann-Whitney
Max Respiratory Support				
ECMO	16 (0.3%)	7 (0.4%)	23 (0.3%)	*P*<0.0001

Mechanical Ventilation	555 (10.7%)	155 (9.0%)	710 (10.3%)	Chi-square
Non-Invasive Ventilation	501 (9.7%)	165 (9.6%)	666 (9.6%)	
High Flow Oxygen	1450 (28.0%)	366 (21.3%)	1816 (26.3%)	
Low Flow Oxygen	1741 (33.6%)	705 (41.0%)	2446 (35.4%)	
Room Air	921 (17.8%)	323 (18.8%)	1244 (18.0%)	
Mortality				
Alive	12496 (95.8%)	3073 (94.9%)	15569 (95.6%)	*P*=0.0271 Fisher's exact test Odds Ratio: 0.815 (95% CI 0.682-0.975)
Deceased	547 (4.2%)	165 (5.1%)	712 (4.4%)	
Median PCR Cycle Threshold				
Abbott Alinity	21.0 n=4200	22.4 n=1101	n=5301	*P*=0.0004 Mann-Whitney
Hologic Panther	21.9 n=1140	24.3 n=374	n=1514	*P*<0.0001 Mann-Whitney
Vaccine				
No vaccine	9483 (72.7%)	2969 (91.7%)	12452 (76.5%)	*P*<0.0001 Chi-square
>7 days past 1st vaccine	472 (3.6%)	133 (4.1%)	605 (3.7%)	
>14 days past 2nd vaccine	3088 (23.7%)	136 (4.2%)	3224 (19.8%)	

Data include 16,281 unique patients with high-quality sequence results between January 1, 2021 and September 20, 2021. BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay

Table 3. Summary of pertinent patient metadata for the 3,346 fully vaccinated patients

	Vaccinated	Not Vaccinated	Total	Statistical Analysis
Median PCR Cycle Threshold				
Abbott Alinity	20.5 n=1244	22.1 n=4364	n=5608	*P*=0.0018 Mann-Whitney
Hologic Panther	22.2 n=378	23.5 n=1235	n=1613	*P*=0.0348 Mann-Whitney
Admission Data				
Admitted	896 (26.8%)	6406 (47.0%)	7302 (43.0%)	*P*<0.0001 Fisher's exact test Odds Ratio: 0.412 (95% CI 0.379-0.448)
Not Admitted	2450 (73.2%)	7213 (53.0%)	9663 (57.0%)	
	Delta Variant	**Other Variants**	**Total**	
No. (%) with data	3088 (92.3%)	258 (7.7%)	3346	
Admission Data				
Admitted	800 (25.9%)	96 (37.2%)	896 (26.8%)	*P*=0.0001 Fisher's exact test Odds Ratio: 0.590 (95% CI 0.453-0.769)
Not Admitted	2288 (74.1%)	162 (62.8%)	2450 (73.2%)	


First Wave
Second Wave
Third Wave
Fourth Wave
Alpha variant
Delta variant
Number of new COVID-19 cases
400
350
300
250
200
150
100
50
0
03/01/2020
05/01/2020
07/01/2020
09/01/2020
11/01/2020
01/01/2021
03/01/2021
05/01/2021
07/01/2021
09/01/2021


A
Cumulative Number of Patients (Delta)
14K
12K
10K
8K
6K
4K
2K
0K
May
Jun
Jul
Aug
Sep
B
Navasota
North Cleveland
Liberty
Houston
Galveston
Bay City
Freeport
1
C
Navasota
North Cleveland
Liberty
Houston
Galveston
Bay City
Freeport
1
4
D
Navasota
North Cleveland
Liberty
Galveston
Freeport
1
41
E
Bryan
Beaumont
Galveston
50 km
1
242
F
Bryan
Galveston
1
595


S1-NTD
S1-RBD
S1
S2
N=4,538
T19R
G142D
E156G
del157-158
L452R
T478K
D614G
P681R
D950N
N=2,380
T19R
T95I
G142D
E156G
del157-158
L452R
T478K
D614G
P681R
D950N
N=1,377
T19R
S12L
G142D
E156G
del157-158
L452R
T478K
D614G
P681R
D950N
N=518
T19R
G142D
E156G
del157-158
A222V
L452R
T478K
D614G
P681R
D950N
N=348
T19R
G142D
E156G
del157-158
A222V
V289I
L452R
T478K
D614G
P681R
D950N
N=234
T19R
V70I
G142D
E156G
del157-158
L452R
T478K
D614G
P681R
D950N
N=148
T19R
G142D
E156G
del157-158
A222V
L452R
T478K
D614G
P681R
D950N
V1264L
N-
-C


A
Cumulative Number of Patients (Lambda)
0
2
4
6
8
Jul 15
Jul 22
Jul 29
Aug 5
Aug 12
B
The Woodlands
Tomball
Spring
Kingwood
Jersey Village
Sheldon
Houston
Baytown
Pasadena
La Porte
Sugar Land
Rosenberg
Pearland
1

C
Cumulative Number of Patients (Mu)
0
10
20
30
40
50
Apr 1
May 1
Jun 1
Jul 1
Aug 1
Sep 1
D
Kingwood
Houston
Pasadena
Pearland
League City
20 km
1
6